Business
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
Analysis showed that liposuction followed by helium plasma RF was associated with higher patient-reported satisfaction with abdominal appearance, lower
About this update from Apyx Medical Corporation
[{"type":"text","content":"Analysis showed that liposuction followed by helium plasma RF was associated with higher patient-reported satisfaction with abdominal appearance, lower abdominoplasty and revision rates, and comparable complication rates versus conventional liposuction alone\nCLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open1. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion). The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with lower rates of abdominoplasty and surgical revisions, while maintaining comparable complication rates to power-assisted liposuction. Key Findings from the 113‑Patient Study Patients treated with Renuvion reported statistically higher satisfaction with reduced appearance of excess skin (Body‑Q score 87.8 vs. 73.8; p=0.03)Among patients who did not undergo abdominoplasty, satisfaction with abdominal appearance was also statistically higher (68.8 vs. 45.0; p=0.039)The rate of patients requiring abdominoplasty was more than 50% lower in the Renuvion group compared to the group receiving power-assisted liposuction only (30.0% vs. 67.1%)Revision rates were significantly lower in the Renuvion group (12.0% vs. 37.5%; p=0.038)Complication rates remained similar between groups (2.5% vs. 2.7%) “This study adds to the growing body of clinical evidence supporting the use of Renuvion in aesthetic body contouring,” said Charlie Goodwin, President and Chief Executive Officer of Apyx Medical. “With more than 2 million liposuction procedures performed globally each year*, these statistically significant improvements in patient satisfaction and reduced revision rates underscore the value Renuvion provides to aesthetic surgeons and their patients.” The retrospective study, led by Pablo D. Huber, MD, evaluated long-term (>12 month) Body-Q® patient-reported outcomes, procedural data, and safety profiles across 1...